⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLN News
Silence Therapeutics Plc American Depository Share
Form 8-K
sec.gov
SLNCF
SLN
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
businesswire.com
SLN
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
businesswire.com
SLN
Form 8-K
sec.gov
SLN
SLNCF
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
globenewswire.com
IONS
ALNY
NVS
BIIB
ARWR
SLN
WVE
VNDA
NSP
TCRT
AMX
CDIO
SRPT
VIR
BNTX
ARCT
GSK
PFE
Form 8-K
sec.gov
SLNCF
SLN
Antiscalants Market worth $6.56 billion by 2031 - Exclusive Report by MarketsandMarkets™
prnewswire.com
DOW
ECL
SLN
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Form 8-K
sec.gov
SLN
SLNCF
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
SLN